The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| XERS | +19.91% | +13.93% | +2.64% | +132% |
| S&P | +19.17% | +69.21% | +11.09% | +53% |
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $85.81M | 42.8% |
| Gross Profit | $72.15M | 50.6% |
| Gross Margin | 84.08% | 4.4% |
| Market Cap | $1.30B | 157.7% |
| Market Cap / Employee | $2.99M | 0.0% |
| Employees | 435 | 10.4% |
| Net Income | $11.08M | 316.7% |
| EBITDA | $19.97M | 315.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $111.04M | 55.0% |
| Accounts Receivable | $51.05M | 26.3% |
| Inventory | 68.7 | 42.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $251.87M | 0.6% |
| Short Term Debt | $6.23M | -70.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 0.15% | 16.5% |
| Return On Invested Capital | -46.97% | 29.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $19.71M | 1023.1% |
| Operating Free Cash Flow | $20.04M | 914.8% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -27.70 | -20.74 | -67.99 | -1509.62 | 8364.53% |
| Price to Sales | 3.76 | 3.03 | 5.43 | 4.84 | 94.60% |
| Price to Tangible Book Value | -5.42 | -4.72 | -9.67 | -11.35 | 243.29% |
| Price to Free Cash Flow TTM | 144.94 | 50.61 | - | ||
| Enterprise Value to EBITDA | 19759.23 | 123.28 | 162.49 | 78.15 | -46.68% |
| Free Cash Flow Yield | 0.7% | 2.0% | - | ||
| Return on Equity | -617.2% | - | |||
| Total Debt | $268.75M | $257.22M | $257.65M | $258.10M | -4.92% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
